Grants per year
Personal profile
Research Interests
As a former social worker turned physician, I am acutely aware of the way in which the psycho-social atmosphere contributes to the treatment of cancer in children, adolescents, and young adults. As a physician, I try to incorporate that view into my treatment of young people with cancer.
In research I have focused on the psychosocial effects of cancer diagnosis and treatment on children, adolescents, and young adults, as well as anthracycline induced cardiotoxicity.
My primary clinical interests include solid tumors, particularly sarcomas, adolescent and young adult oncology, and survivorship.
Certifications and Licenses
| Pediatric Hematology-Oncology | |
| Pediatrics |
Training Experience
| 2005 | Residency, Children's Hospital of Philadelphia |
| 2008 | Fellowship, Children's Hospital of Philadelphia |
Education/Academic qualification
MD, Hahnemann University
… → 2002
Research interests
- Oncology
Fingerprint Dive into the research topics where Jennifer L Reichek is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 4 Similar Profiles
Neuroblastoma
Medicine & Life Sciences
irinotecan
Medicine & Life Sciences
temozolomide
Medicine & Life Sciences
docetaxel
Medicine & Life Sciences
Osteosarcoma
Medicine & Life Sciences
gemcitabine
Medicine & Life Sciences
Mutation
Medicine & Life Sciences
Pediatrics
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Grants 2013 2021
Supportive Oncology Initiative for Children with Cancer
Pillay Smiley, N. & Reichek, J. L.
7/1/17 → 6/30/18
Project: Research project
Supportive Oncology Initiative for Children with Cancer
Pillay Smiley, N. & Reichek, J. L.
1/1/16 → 6/30/17
Project: Research project
Research Output 2011 2019
1
Citation
(Scopus)
Critical Illness and Cardiac Dysfunction in Anthracycline-Exposed Pediatric Oncology Patients
Wolfe, K. K., Reichek, J. L. & Marsillio, L. E., Jul 1 2019, In : Pediatric Critical Care Medicine. 20, 7, p. 595-602 8 p.Research output: Contribution to journal › Article
Anthracyclines
Critical Illness
Pediatrics
Mortality
Artificial Respiration
6
Citations
(Scopus)
Late Effects in Pediatric High-risk Neuroblastoma Survivors after Intensive Induction Chemotherapy Followed by Myeloablative Consolidation Chemotherapy and Triple Autologous Stem Cell Transplants
Armstrong, A. E., Danner-Koptik, K., Golden, S., Schneiderman, J., Kletzel, M., Reichek, J. & Gosiengfiao, Y., Jan 1 2018, In : Journal of pediatric hematology/oncology. 40, 1, p. 31-35 5 p.Research output: Contribution to journal › Article
Consolidation Chemotherapy
Induction Chemotherapy
Neuroblastoma
Survivors
Stem Cells
Prolonged response to sorafenib in a patient with refractory metastatic osteosarcoma and a somatic PDGFRA D846V mutation
Armstrong, A. E., Walterhouse, D. O., Leavey, P. J., Reichek, J. & Walz, A. L., Jan 1 2018, (Accepted/In press) In : Pediatric Blood and Cancer. 66, 1, e27493.Research output: Contribution to journal › Article
Osteosarcoma
Mutation
Biomarkers
Recurrence
Terminology
12
Citations
(Scopus)
Clinical research participation among adolescent and young adults at an NCI-designated Comprehensive Cancer Center and affiliated pediatric hospital
Sanford, S. D., Beaumont, J. L., Snyder, M. A., Reichek, J. & Salsman, J. M., May 1 2017, In : Supportive Care in Cancer. 25, 5, p. 1579-1586 8 p.Research output: Contribution to journal › Article
Pediatric Hospitals
Young Adult
Research
Neoplasms
Insurance
5
Citations
(Scopus)
Treatment of neuroblastoma in congenital central hypoventilation syndrome with a PHOX2B polyalanine repeat expansion mutation: New twist on a neurocristopathy syndrome
Armstrong, A. E., Weese-Mayer, D. E., Mian, A., Maris, J. M., Batra, V., Gosiengfiao, Y., Reichek, J., Madonna, M. B., Bush, J. W., Shore, R. M. & Walterhouse, D. O., Nov 1 2015, In : Pediatric Blood and Cancer. 62, 11, p. 2007-2010 4 p.Research output: Contribution to journal › Article
Homeobox Genes
Neuroblastoma
Mutation
Hirschsprung Disease
Therapeutics